Summit Therapeutics to Present Phase 1b Clinical and Preclinical DMD Data at the 20th International Congress of the World Mus...
24 September 2015 - 9:00PM
Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy ('DMD') and Clostridium difficile infection,
today announced that it will present additional clinical data from
its Phase 1b modified diet trial of SMT C1100 for the treatment of
DMD, as well as preclinical data supporting SMT C1100 and the
broader utrophin modulation pipeline, at the 20th International
Congress of the World Muscle Society, taking place 30 September-4
October 2015 in Brighton, UK.
The posters will be available in the Corn Exchange, Brighton
from the beginning of the conference on 30 September 2015 and a
press release containing key data from the presentations will be
issued on that date. Details of the poster presentations are as
follows:
Clinical:
Date & Time: Friday 2
October, 3:00-4:30pm BST |
Session: Guided Poster
Session 3 |
Abstract Number: G.P.
249 |
Title: Utrophin modulators
to treat Duchenne muscular dystrophy (DMD): Results from a Phase 1b
Clinical Trial of SMT C1100 |
Authors: F. Muntoni; S.
Spinty; H. Roper; I. Hughes; V. Ricotti; B. Tejura; G. Layton; K.
Davies and J. Tinsley |
Preclinical:
Date & Time: Friday 2
October, 3:00-4:30pm BST |
Session: Guided Poster
Session 3 |
Abstract Number: G.P.
216 |
Title: Biomarker development
to support the clinical development of utrophin modulators for
Duchenne muscular dystrophy therapy |
Authors: J. Tinsley; N.
Janghra; J. Morgan; C. Sewry; F. Muntoni; D. Elsey; F. Wilson; K.
Davies |
|
Date & Time: Friday 2
October, 3:00-4:30pm BST |
Session: Guided Poster
Session 3 |
Abstract Number: G.P.
245 |
Title: Second generation
utrophin modulator for the therapy of Duchenne muscular
dystrophy |
Authors: S. Guiraud; S.
Squire; B. Edwards; H. Chen; D. Burns; N. Shah; A. Babbs; S.
Davies; G. Wynne; A. Russell; D. Elsey; F. Wilson; J. Tinsley; K.
Davies |
|
Date & Time: Friday 2
October, 3:00-4:30pm BST |
Session: Guided Poster
Session 3 |
Abstract Number: G.P.
246 |
Title: Utrophin modulators
significantly improve muscular dystrophy in the mdx diaphragm |
Authors: S. Guiraud; H.
Chen; S. Squire; B. Edwards; D. Burns; N. Shah; S. Davies; G.
Wynne; A. Russell; D. Elsey; F. Wilson; J. Tinsley; K. Davies |
|
Date & Time: Friday 2
October, 3:00-4:30pm BST |
Session: Guided Poster
Session 3 |
Abstract Number: G.P.
247 |
Title: Discovery of small
molecule utrophin modulators for the therapy of Duchenne muscular
dystrophy (DMD) |
Authors: N. Araujo; A.
Vuorinen; R. Fairclough; S. Guiraud; J. Donald; C. Cairnduff; D.
Hewings; F. Martinez; K. Csatayova; N. Willis; S. Squire; A. Babbs;
B. Edwards; N. Shah; J. Tinsley; F. Wilson; S. Davies; G. Wynne; K.
Davies; A. Russell |
About the Phase 1b Modified Diet Trial
The Phase 1b randomised, placebo controlled clinical trial was
designed to evaluate the blood plasma levels of SMT C1100 in
paediatric patients with DMD. Patients and their caregivers were
provided with specific dietary guidance on recommended balanced
proportions of fats, proteins and carbohydrates. The trial enrolled
a total of 12 patients aged between 5 and 13 years, divided equally
into three dose cohorts, at trial sites in the UK. Patients were
randomised to three groups over 14-day treatment periods during
which each patient received two different doses of SMT C1100 and a
placebo control. There was a washout period of at least 14 days in
between each of the treatment periods.
About Utrophin Modulation in DMD
DMD is a progressive muscle wasting disease that affects around
50,000 boys in the developed world. The disease is caused by
different genetic faults in the gene that encodes dystrophin, a
protein that is essential for the healthy function of all muscles.
There is currently no cure for DMD and life expectancy is into the
late twenties. Utrophin protein is functionally and structurally
similar to dystrophin. In preclinical studies, the continued
expression of utrophin has a meaningful, positive effect on muscle
performance. Utrophin modulation has the potential to slow down or
even stop the progression of DMD, regardless of the underlying
dystrophin mutation. It is also expected that utrophin modulation
could potentially be complementary to other therapeutic approaches
for DMD.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease Duchenne muscular dystrophy and the infectious
disease C. difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit |
|
Glyn Edwards / Richard Pye (UK office) |
Tel: +44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US
office) |
+1 617 255 4455 |
|
|
Cairn Financial Advisers
LLP |
|
(Nominated Adviser) |
|
Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 77148 7900 |
|
|
N+1 Singer |
|
(Broker) |
|
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
|
|
Peckwater PR |
|
(Financial public relations, UK) |
Tel: +44 (0)7879 458 364 |
Tarquin Edwards |
tarquin.edwards@peckwaterpr.co.uk |
|
|
MacDougall Biomedical
Communications |
|
(US media contact) |
Tel: +1 781 235 3060 |
Chris Erdman |
cerdman@macbiocom.com |
-END-
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024